SCHEMBL6429046

SCHEMBL6429046

O=C(Nc1cccc(O)c1)c1ccc([N+](=O)[O-])o1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.74
MEN1 O00255 6/20 0.71
KMT2A Q03164 6/20 0.71
PAX8 Q06710 3/20 0.71
MAPT P10636 4/20 0.67
LMNA P02545 3/20 0.64
HTT P42858 2/20 0.64
RAB9A P51151 2/20 0.64
KDM4E B2RXH2 2/20 0.64
GAA P10253 3/20 0.64
MITF O75030 3/20 0.64
NPC1 O15118 2/20 0.64
NFKB1 P19838 1/20 0.64
NFKB2 Q00653 1/20 0.64
RELA Q04206 1/20 0.64
ALDH1A1 P00352 3/20 0.59
POLB P06746 2/20 0.59
MAPK1 P28482 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
DDIT3 P35638 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22804220 0.85 JAK2 (0.73) JAK2MEN1KMT2APAX8MAPT
SCHEMBL22822561 0.85 JAK2 (0.77) JAK2MEN1KMT2APAX8MAPT
SCHEMBL6428809 0.85 JAK2 (0.73) JAK2MEN1KMT2APAX8MAPT
SCHEMBL6427451 0.85 JAK2 (0.73) JAK2MEN1KMT2APAX8MAPT
SCHEMBL6428416 0.85 JAK2 (0.73) JAK2MEN1KMT2APAX8MAPT
SCHEMBL13219526 0.85 JAK2 (1.00) JAK2MEN1KMT2APAX8MAPT
SCHEMBL1520209 0.84 DDIT3 (0.78) JAK2MEN1KMT2APAX8MAPT
SCHEMBL22804228 0.84 JAK2 (0.75) JAK2MEN1KMT2APAX8MAPT
SCHEMBL22822855 0.83 JAK2 (0.73) JAK2MEN1KMT2APAX8MAPT
SCHEMBL22822771 0.83 JAK2 (0.70) JAK2MEN1KMT2APAX8MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12428389-B2 Diarylamide compound and application thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2025-09-30 US claimed
US-20230045031-A1 Diarylamide Compound and Application Thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-02-09 US claimed
EP-3984534-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF Peking University (CN) 2022-04-20 EP claimed
CN-112107568-B Diaryl amide compound and application thereof 北京龙嘉博创医药科技有限公司 2022-03-25 CN claimed
WO-2020253802-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF 北京大学 2020-12-24 WO claimed
CN-112107568-A Diaryl amide compound and application thereof 北京大学 2020-12-22 CN claimed
US-20050026968-A1 Heterocyclic amides with anti-tuberculosis activity UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-02-03 US claimed
US-12428389-B2 Diarylamide compound and application thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2025-09-30 US disclosed
US-20230045031-A1 Diarylamide Compound and Application Thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-02-09 US disclosed
US-20230045031-A1 Diarylamide Compound and Application Thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2023-02-09 US disclosed
EP-3984534-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF Peking University (CN) 2022-04-20 EP disclosed
EP-3984534-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF Peking University (CN) 2022-04-20 EP disclosed
CN-112107568-B Diaryl amide compound and application thereof 北京龙嘉博创医药科技有限公司 2022-03-25 CN disclosed
WO-2020253802-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF 北京大学 2020-12-24 WO disclosed
WO-2020253802-A1 DIARYLAMIDE COMPOUND AND APPLICATION THEREOF 北京大学 2020-12-24 WO disclosed
CN-112107568-A Diaryl amide compound and application thereof 北京大学 2020-12-22 CN disclosed
US-20050222408-A1 Heterocyclic amides with anti-tuberculosis activity UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-10-06 US disclosed
US-20050026968-A1 Heterocyclic amides with anti-tuberculosis activity UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222408-A1 Heterocyclic amides with anti-tuberculosis activity TST, KAT5, NDUFS5 JAK2 3291/4885MEN1 4703/4885KMT2A 2545/4885
US-12428389-B2 Diarylamide compound and application thereof SLC14A1, SLC28A1, SLC28A2 JAK2 3981/4885MEN1 3485/4885KMT2A 3036/4885
US-20050026968-A1 Heterocyclic amides with anti-tuberculosis activity TST, KAT5, HDAC5 JAK2 2968/4885MEN1 4749/4885KMT2A 2476/4885
US-20230045031-A1 Diarylamide Compound and Application Thereof SLC14A1, SLC28A1, SLC28A2 JAK2 3981/4885MEN1 3485/4885KMT2A 3036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.